Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940393 | 0.90 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL5117791 | 0.90 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL3930240 | 0.89 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL5109354 | 0.87 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL14289452 | 0.85 | TRPV1 (0.72) | TRPV1NPC1RAB9A | |
| SCHEMBL14320237 | 0.85 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL14289454 | 0.85 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL14289511 | 0.84 | TRPV1 (0.76) | TRPV1 | |
| SCHEMBL14289462 | 0.83 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL14289503 | 0.83 | TRPV1 (0.74) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044086-A2 | THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-08 | — | — | EP | claimed |
| WO-2008005303-A2 | THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-10 | — | — | WO | claimed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | claimed |
| WO-2008005303-A2 | THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885NPC1 772/4885RAB9A 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.